P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P ¼ 0.024, 0.014, 0.006, respectively, w 2 -test or Fisher's exact test). We also found significantly higher (P ¼ 0.019, w 2 -test) T allele frequency in breast cancer patients (n ¼ 221) than in controls (n ¼ 113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n ¼ 38; P ¼ 0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n ¼ 102; P ¼ 0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.
Introduction
Breast cancer remains the most commonly diagnosed cancer (excluding nonmelanoma skin cancers) in the female populations of industrialized countries. 1, 2 Although breast cancer mortality has declined, carcinoma of the breast continues to represent a major threat to the lives and productivity of women.
Genetics has a significant function in several aspects of breast cancer including the risk of developing the disease (such as genetic mutations BRCA1, BRCA2, TP53, PTEN), prognosis at the time of diagnosis and also in response to specific treatments and the likelihood of adverse reactions to certain therapies. [3] [4] [5] The number of effective treatments for breast cancer is on the rise and breast cancer is often regarded as one of the most chemoresponsive tumors. However, interindividual variations in therapeutic response and drug toxicity are important problems in breast cancer therapy. Antitumor activity or safety of specific agents may depend not only on certain clinical and pathological characteristics of the tumor (such as lymph node metastases, tumor size, grade, hormone receptors, epidermal growth factor receptor-HER-2), treatment (drug dose and schedule) but also on drug metabolizing enzymes and transporters.
Recent studies have shown that genetic variants of some members of the adenosine triphosphate-binding cassette protein superfamily of membrane transporters can contribute to cancer susceptibility and interindividual differences in chemotherapy response. 6 The product of the MDR1 gene, P-glycoprotein (PGP), represents the most widely studied membrane protein of the adenosine triphosphate-binding cassette transporter family. 7 It is an active efflux pump for a variety of toxins as well as dietary and environmental carcinogens, and drugs (including antineoplastic agents such as anthracyclines, vinca alkaloids, epipodophyllotoxins, tamoxifen). 8, 9 PGP is found in many organs and tissues, including the apical brush border of luminal cells in the lower digestive system, the liver, proximal renal tubules, endothelial cells in the blood-brain barrier, the placenta, the testes, and also in breast and hematopoietic cells. 10, 11 PGP being found in these aforementioned tissues suggests that it has a function in excreting potentially toxic or unnecessary xenobiotics and metabolites from cells. Currently, 4100 variants in the MDR1 gene have been reported. One of these, a silent single nucleotide polymorphism (SNP) localized in exon 26 (C3435T) has been found to be associated with altered PGP function. 12, 13 However, a plethora of published studies attempting to identify the relationship of this particular SNP to mRNA or protein expression, the pharmacokinetics of PGP-substrate drugs, cancer risk and clinical outcomes related to substratedrug resistance or side effects, have produced mixed and inconsistent results. 14, 15 High MDR1 expression in nonneoplastic breast tissue and also in neoplastic breast tissue, the role of some chemical substances in the carcinogenesis of breast carcinoma and frequent administration of PGP substrates in the breast cancer therapy, suggest that this protein may also represent a role in the etiology and therapeutic outcome of breast cancer.
On the basis of earlier published data, our study was focused on determining the relevance of the MDR1 (C3435T) polymorphism to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, therapeutic response, and hematologic toxicities after anthracycline-based chemotherapy.
Materials and methods

Study population
Blood samples were collected from 221 females (median: 55 years, range: 31-93 years) with a pathology-confirmed diagnosis of breast cancer. Blood samples of 113 healthy female donors were collected as controls. The control group was age-matched to patients (median: 54 years, range: 29-82 years). All cases and controls were of Slovak origin (Caucasians) from different regions of Eastern Slovakia. The participation of each subject was voluntary and could be cancelled by any individual at any time during this study (according to the Helsinki II declaration). The local ethics committee approved the research protocol for this study and all volunteers signed the study informed consent form.
Data collection
A clinical oncologist collected clinical and pathological characteristics, therapeutic response and incidence of hematologic toxicities after chemotherapy retrospectively from medical records. Complete information about the treatment was obtained from 174 breast cancer patients.
Chemotherapy treatments
Although patients received different types of chemotherapy, hormones, radiotherapy or biological treatment, therapeutic outcome, and hematologic toxicities were evaluated only in those patients who received anthracycline-based (epirubicin ¼ E or doxorubicin ¼ A) chemotherapy. Overall 111 patients received anthracycline-based chemotherapy (neoadjuvant therapy: n ¼ 38; neoadjuvant and/or adjuvant therapy: n ¼ 102; palliative therapy: n ¼ 9). Usually anthracycline-based chemotherapy consists of 5-fluorouracil, the anthracycline agent and cyclophosphamide (FAC, FEC or AC regimens) combined with radiotherapy and in some cases with sequential tamoxifen therapy (another PGP substrate).
Evaluation of chemotherapy response and toxicity Therapeutic response after neoadjuvant therapy was assessed using Response Evaluation Criteria in Solid Tumor guidelines. In this study, responsive patients were considered to be those who showed complete or partial response, whereas those with stable or progressive disease were classified as nonresponders. Time to progression (TTP) was defined as the time elapsed between time after a disease was diagnosed and an occurrence of metastases. Hematologic toxicities (anemia, leukopenia, neutropenia and thrombocytopenia) were evaluated according to WHO criteria (grades 0, 1, 2, 3, 4).
DNA extraction
Blood samples were taken from anticoagulated (Na 2 EDTA) peripheral venous blood and genomic DNA was extracted using the standard phenol/chloroform extraction method. Because of acquisition of new and better equipment in our laboratory, samples collected more recently were extracted using the Wizard Genomic DNA Purification Kit (Promega Corporation, USA).
MDR1 (C3435T) polymorphism genotyping
The SNP in MDR1 (C3435T in exon 26) was analyzed by PCR-RFLP assay using the primer sequences 
Statistical analyses
SPSS software for Windows (version 15.0, USA) was used for statistical analyses. The differences in genotype and allele frequencies were determined using the w 2 -test or Fisher's exact test. Odds ratios and the corresponding 95% CI were used for the calculation of the relative associations. TTP was estimated using the Kaplan-Meier method and compared by log-rank test. All tests were two-sided and P-values of o0.05 were taken as statistically significant.
Results
Genotype and allelic distribution of MDR1 C3435T polymorphism Overall genotype and allele frequencies for the MDR1 C3435T polymorphism in breast cancer patients and controls are shown in Table 1 . The CC genotype was found in 46 (20.8%) patients and in 35 (31.0%) control subjects. The C allele frequency was 45.2% for breast cancer patients and 54.9% for healthy donors; the T allele frequency was 54.8% for patients and 45.1% for controls. The difference in allele and genotype frequencies between controls and patients was found to be statistically significant (C vs T: P ¼ 0.019; CC vs TT: P ¼ 0.020; CC vs CT þ TT: 0.040). The TT homozygotes appeared to be at higher risk of breast cancer (OR ¼ 2.12; 95% CI ¼ 1.12-4.03). The test for the Hardy-Weinberg equilibrium in both groups of subjects did not show a significant deviation from the HardyWeinberg equilibrium.
Patient characteristics according to the MDR1 (C3435T) polymorphism Clinical and pathological characteristics of the patients differentiated according to MDR1 genotypes and alleles are shown in Table 2 . A significant association between patients with ductal invasive carcinoma (DIC) and lobular invasive carcinoma was observed (T vs C: P ¼ 0.024 (OR ¼ 2.17; 95% CI ¼ 1.09-4.32)). There was also a significant association between allele frequency and stage of disease and also histological grade. A lower frequency of T allele was detectable in patients with stage IV in comparison to stages 0-III and in patients with grade 3 in comparison to grades 1 þ 2 (P ¼ 0.014 (OR ¼ 0.29 (0.11-0.76); P ¼ 0.006 (OR ¼ 0.47 (0.27-0.81), respectively). No other significant differences were found across patients differentiated according to MDR1 (C3435T) polymorphism.
MDR1 gene variants and therapeutic response to neoadjuvant chemotherapy A statistically significant association was found between polymorphism of MDR1 C3435T in exon 26 and successful treatment with neoadjuvant anthracycline-based chemotherapy (n ¼ 38 subjects), independently of histo- MDR1 gene variants and time to progression Time to progression was evaluated using the Kaplan-Meier method in patients who received anthracycline-based neoadjuvant and/or adjuvant chemotherapy (n ¼ 102). The appearance of distant metastases was considered as defining progression (n ¼ 34). Median time to progression in patients with CC genotype was 121.8 months (95% CI ¼ 48.0-195.6), whereas in the CT þ TT group it was only 43.25 months (95% CI ¼ 40.7-45.8). This difference was found to be statistically significant (log-rank; P ¼ 0.049) (Figure 2 ). The hazard ratio for progression in CT, TT group vs the wild-type CC was 2.28. Independently, we tested progression-free survival in patients with DIC after defined chemotherapy. A similar trend was observed although no statistically significant association was detectable (Figure 2 ).
MDR1 gene variants and hematologic toxicities
All patients who received anthracycline-based chemotherapy (n ¼ 111) were included in the hematologic toxicity analysis according to WHO criteria. Neutropenia grade X2 was observed as the most frequent hematologic toxicity (n ¼ 37, 33.3%). Some patients (n ¼ 26) experienced more than one type of hematologic toxicity. A separate analysis was performed for grades 3-4 toxicities. No significant Fisher's exact test. *A significant association.
MDR1 (C3435T) polymorphism and breast cancer
M Cizmarikova et al differences in hematologic toxicities were found in samples differentiated by the genotype and allele frequencies of MDR1 C3435T polymorphism (Tables 4 and 5 ).
Discussion
Genotypic variation has a key function in human phenotypic variability such as cancer susceptibility and response to therapy. During recent years, considerable progress has been made in the understanding of transporter-mediated processes for a wide variety of xenobiotics including chemical carcinogens and anticancer agents. The role of the MDR1 gene product, a transmembrane active efflux pump, PGP, has also been shown in many studies. 16, 17 Recently, a silent C3435T polymorphism in exon 26 of MDR1 has been reported to be associated with altered PGP expression and function, 12, 13 thereby influencing the susceptibility to various diseases, including cancer 14, [18] [19] [20] as well as therapeutic outcome. 6, 15 Several studies have confirmed MDR1 mRNA and protein expression in normal breast tissue and also in neoplastic breast tissue. 11 Exposure to some dietary and environmental carcinogens is thought to be involved in the pathogenesis of breast cancer 21 and PGP-transported drugs are used in breast cancer treatment. 5 However, little is known about the impact of the C3435T polymorphism on breast cancer development, treatment efficacy, and toxicity after therapy with PGP substrates.
With respect to the data that has been published earlier, we evaluated genotype and allele frequencies of the MDR1 (C3435T) polymorphism in breast cancer patients (n ¼ 221) in comparison to healthy volunteer subjects (n ¼ 113). The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis confirmed a significant prevalence of the T allele in the breast cancer group compared with controls (P ¼ 0.018) and that the TT homozygotes appeared to be at increased risk of breast cancer (OR ¼ 2.12). Our results are consistent with the hypothesis that the T allele (generally associated with lower MDR1 expression and PGP function) offers less protection from the accumulation of carcinogenic materials in tissues with documented MDR1 expression. Similarly, Turgut et al. 22 found higher T allele frequency in breast cancer patients in comparison to controls (P ¼ 0.009). Our results were gained in contrast to work carried out by other researchers, who observed no significant differences in genotype and allele frequencies between Iranian patients with breast cancer and control subjects (P ¼ 0.744 and 0.590, respectively). 23 Furthermore, the C3435T genotype-related disease risk has been studied in several other cancers (renal cell carcinoma, colon cancer, lung cancer, acute lymphoblastic and myeloid leukemia, glioma) with mixed and inconsistent results. 14, [18] [19] [20] [24] [25] [26] Several studies have considered the relationship between MDR1 expression and C3435T polymorphism examining clinical and pathological characteristics in patients with breast cancer. 11, 22, 23 However, the correlation was either nonsignificant or there was insufficient data. A significant association between patients with DIC and lobular invasive carcinoma was observed (T vs C: P ¼ 0.024) in the group we tested. Also, a significantly lower frequency of the T allele was detectable in patients with stage IV in comparison to stages 0-III and in patients with grade 3 in comparison with grades 1 þ 2 (P ¼ 0.014 and 0.006, respectively). However, no difference in PGP expression was described between stage IV and other stages of breast cancer in the literature.
11
Recently, MDR1 genotyping has attracted researchers' attention to the possibility of personalized treatment through identification of responders/nonresponders to a certain class of pharmacotherapy. It has been reported that Table 4 Hematologic toxicities (grades 0-1 vs grades 2-4) in samples differentiated according to MDR1 (C3435T) polymorphism
Hematologic toxicity (grades 2-4)
Genotypes Alleles P-value Table 5 Hematologic toxicities (grades 0-2 vs grades 3-4) in samples differentiated according to MDR1 (C3435T) polymorphism
Hematologic toxicity (grades 3-4)
Genotypes Alleles P-value MDR1 (C3435T) polymorphism and breast cancer M Cizmarikova et al tumors arising in organs that normally express high levels of PGP, such as kidneys, adrenals or the colon are known to be intrinsically resistant to chemotherapy. 27 The role of PGP in human breast cancer is however unclear. Therefore, in this analysis we examined the therapeutic response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients in relation to the C3435T polymorphism. Surprisingly, significantly better response rates (P ¼ 0.021) according to Response Evaluation Criteria in Solid Tumor criteria were observed in homozygotes for the C allele (all were classified as responders). In contrast, Kafka et al. 28 revealed that the TT genotype at position 3435 significantly correlated (P ¼ 0.029) with clinical complete response to preoperative chemotherapy with anthracyclines alone or in combination with taxanes. Rodrigues et al. 29 did not find a significant correlation with SNP C3435T and clinical response in breast cancer patients, although the complete pathological response showed only the polymorphic genotype. It should be noted that nowadays breast cancer is detected in its earlier stages. Therefore, a number of patients with locally advanced breast cancer who need neoadjuvant therapy are limited in all published studies. Larger sample size studies must be carried out to determine the true role of MDR1 C3435T SNP in the neoadjuvant treatment of breast cancer.
Time to progression after anthracycline-based chemotherapy (n ¼ 102) was also evaluated. The median time to progression (TTP) in the CC genotype group was 121.8 months, whereas in the CT þ TT group it was only 43.25 months. This difference was found to be statistically significant (P ¼ 0.049, log-rank). Independently, TTP was evaluated in a subgroup of patients with DIC, which showed a similar but nonsignificant trend. Similarly, Turgut et al. 22 did not find any statistically significant difference between particular MDR1 C3435T genotypes in patients with DIC.
Occurrence of toxic side effects after anthracycline-based chemotherapy is another important problem in breast cancer patients. Hematologic toxicities were shown to be the most frequent unwanted life threatening effect of defined chemotherapy in the group we tested (58% of patients with any type of hematologic toxicity). Moreover, the documented MDR1 expression and PGP activity in lymphocytes, granulocytes, monocytes and several other blood cells suggests that PGP may have a physiological function, protecting these cells against endogenous and exogenous toxins including cytotoxic drugs. 30, 31 Hematologic toxicities after anthracycline-based chemotherapy in relation to C3435T polymorphism has not yet been analyzed in breast cancer patients. In this study, no significant differences in hematologic toxicities were found in groups differentiated according to genotype and allele frequency of C3435T polymorphism. It is possible that other anticancer, non-PGP substrate drugs of this regimen or comorbidity could contribute to hematologic toxicities and influence our results.
In conclusion, the results of this study show that the MDR1 C3435T polymorphism could have a function in the risk of developing breast cancer risk and interindividual variability in therapeutic outcome after anthracycline-based chemotherapy of the same patients. The genotype that was associated with a higher risk of developing breast cancer was also a predictor of the worst therapeutic outcome. Larger prospective studies or meta-analyses as well as in vitro and in vivo functional studies are needed to confirm and compare the results obtained and to identify the physiological and molecular pathways leading to our findings.
